Pixium Vision SA, a bioelectronics firm focused on innovative vision systems for sight-impaired individuals, will soon initiate a tender process to sell its business due to a lack of financial investors. The company will request a shift from safeguard proceedings to receivership. Offers can be submitted until November 20, 2023. Interested parties can contact court-appointed administrators for access to an electronic data room after signing a confidentiality agreement. Regular updates on the procedure and the company’s financial status will be provided to the market.
Pixium Vision SA (Euronext Growth Paris – FR001400JX97; Mnemo: ALPIX) (the “Company”), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces that a tender process (appel d’offres) for the purpose of finding buyers to acquire the Company’s business will be published tomorrow.
Having been unable to find financial investors within the restricted timeframe and in line with the Company’s needs, a safeguard plan is no more an option. As a result, the Company will be requesting the conversion of safeguard proceedings (procédure de sauvegarde) into receivership (redressement judiciaire).
In this context, the deadline for submission of offers has been set by the court-appointed administrators to November 20, 2023 at 12:00 p.m. (noon).
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Interested candidates are invited to contact the court-appointed administrators, SCP Abitbol & Rousselet, represented by Joanna Rousselet, and Selarl FHB, represented by Hélène Bourbouloux.
Access to an electronic data room will be granted once the candidate has signed a confidentiality agreement and submitted a brief presentation of interest.
The market will be regularly informed of developments in the procedure and, more generally, of the Company’s financial situation.
Source: Biospace
